The 2bPrecise module initially will be rolled out to four practices over the next few months.
The platform uses genetic data from molecular labs and clinical information from EHRs; doctors can use the data to make decisions about drugs they may prescribe for patients.
“We recognize that precision medicine represents a new standard in health care,” said Rick Salas, CEO of USOA. “We’re committed to delivering the services, technologies and infrastructure orthopedic surgeons need so they can factor patient genetic profiles into their diagnostic and treatment decisions.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
